annual total liabilities:
$1.70B+$50.19M(+3.04%)Summary
- As of today (June 22, 2025), HALO annual total liabilities is $1.70 billion, with the most recent change of +$50.19 million (+3.04%) on December 31, 2024.
- During the last 3 years, HALO annual total liabilities has risen by +$792.18 million (+87.29%).
- HALO annual total liabilities is now at all-time high.
Performance
HALO Total liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly total liabilities:
$1.71B+$14.61M(+0.86%)Summary
- As of today (June 22, 2025), HALO quarterly total liabilities is $1.71 billion, with the most recent change of +$14.61 million (+0.86%) on March 31, 2025.
- Over the past year, HALO quarterly total liabilities has increased by +$50.54 million (+3.04%).
- HALO quarterly total liabilities is now -3.01% below its all-time high of $1.77 billion, reached on September 30, 2022.
Performance
HALO quarterly total liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Total liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
HALO Total liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +3.0% | +3.0% |
| 3 y3 years | +87.3% | +90.0% |
| 5 y5 years | +258.5% | +294.7% |
HALO Total liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +87.3% | -3.0% | +90.0% |
| 5 y | 5-year | at high | +296.3% | -3.0% | +306.8% |
| alltime | all time | at high | >+9999.0% | -3.0% | >+9999.0% |
HALO Total liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $1.71B(+0.9%) |
| Dec 2024 | $1.70B(+3.0%) | $1.70B(+2.1%) |
| Sep 2024 | - | $1.67B(-0.9%) |
| Jun 2024 | - | $1.68B(+1.0%) |
| Mar 2024 | - | $1.66B(+0.9%) |
| Dec 2023 | $1.65B(-1.3%) | $1.65B(+0.4%) |
| Sep 2023 | - | $1.64B(-1.0%) |
| Jun 2023 | - | $1.66B(+1.6%) |
| Mar 2023 | - | $1.63B(-2.3%) |
| Dec 2022 | $1.67B(+84.2%) | $1.67B(-5.4%) |
| Sep 2022 | - | $1.77B(+18.8%) |
| Jun 2022 | - | $1.49B(+65.0%) |
| Mar 2022 | - | $901.99M(-0.6%) |
| Dec 2021 | $907.48M(+111.6%) | $907.48M(+0.4%) |
| Sep 2021 | - | $903.75M(-0.3%) |
| Jun 2021 | - | $906.12M(+0.8%) |
| Mar 2021 | - | $898.99M(+109.6%) |
| Dec 2020 | $428.88M(-9.5%) | $428.88M(+0.9%) |
| Sep 2020 | - | $425.04M(+0.9%) |
| Jun 2020 | - | $421.42M(-3.0%) |
| Mar 2020 | - | $434.31M(-8.4%) |
| Dec 2019 | $474.11M(+147.8%) | $474.11M(+279.3%) |
| Sep 2019 | - | $125.00M(-20.8%) |
| Jun 2019 | - | $157.78M(-6.7%) |
| Mar 2019 | - | $169.06M(-11.7%) |
| Dec 2018 | $191.36M(-38.6%) | $191.36M(-6.5%) |
| Sep 2018 | - | $204.77M(-6.9%) |
| Jun 2018 | - | $219.83M(-4.6%) |
| Mar 2018 | - | $230.41M(-26.1%) |
| Dec 2017 | $311.58M(+6.0%) | $311.58M(+9.4%) |
| Sep 2017 | - | $284.76M(-0.6%) |
| Jun 2017 | - | $286.62M(+0.5%) |
| Mar 2017 | - | $285.27M(-3.0%) |
| Dec 2016 | $294.00M(+111.8%) | $294.00M(-0.2%) |
| Sep 2016 | - | $294.49M(+2.9%) |
| Jun 2016 | - | $286.21M(+2.4%) |
| Mar 2016 | - | $279.62M(+101.5%) |
| Dec 2015 | $138.79M(+11.4%) | $138.79M(+9.3%) |
| Sep 2015 | - | $126.94M(+2.5%) |
| Jun 2015 | - | $123.82M(+1.8%) |
| Mar 2015 | - | $121.58M(-2.4%) |
| Dec 2014 | $124.63M(+2.3%) | $124.63M(-0.0%) |
| Sep 2014 | - | $124.69M(-1.6%) |
| Jun 2014 | - | $126.75M(-3.2%) |
| Mar 2014 | - | $130.94M(+7.5%) |
| Dec 2013 | $121.78M | $121.78M(+7.2%) |
| Sep 2013 | - | $113.63M(+18.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2013 | - | $96.24M(+13.0%) |
| Mar 2013 | - | $85.19M(-0.8%) |
| Dec 2012 | $85.87M(+56.5%) | $85.87M(+51.2%) |
| Sep 2012 | - | $56.79M(+8.1%) |
| Jun 2012 | - | $52.51M(-2.1%) |
| Mar 2012 | - | $53.66M(-2.2%) |
| Dec 2011 | $54.86M(-22.7%) | $54.86M(+7.2%) |
| Sep 2011 | - | $51.19M(-26.3%) |
| Jun 2011 | - | $69.46M(+3.0%) |
| Mar 2011 | - | $67.42M(-5.0%) |
| Dec 2010 | $70.99M(+1.1%) | $70.99M(+8.6%) |
| Sep 2010 | - | $65.39M(-0.3%) |
| Jun 2010 | - | $65.60M(-4.0%) |
| Mar 2010 | - | $68.36M(-2.7%) |
| Dec 2009 | $70.25M(+14.8%) | $70.25M(+1.1%) |
| Sep 2009 | - | $69.51M(-0.5%) |
| Jun 2009 | - | $69.86M(+7.5%) |
| Mar 2009 | - | $65.00M(+6.2%) |
| Dec 2008 | $61.18M(+33.9%) | $61.18M(+22.7%) |
| Sep 2008 | - | $49.87M(+2.0%) |
| Jun 2008 | - | $48.90M(-1.4%) |
| Mar 2008 | - | $49.60M(+8.6%) |
| Dec 2007 | $45.69M(+98.6%) | $45.69M(+1.4%) |
| Sep 2007 | - | $45.08M(+35.1%) |
| Jun 2007 | - | $33.37M(+1.2%) |
| Mar 2007 | - | $32.96M(+43.3%) |
| Dec 2006 | $23.01M(+899.0%) | $23.01M(+734.6%) |
| Sep 2006 | - | $2.76M(+13.7%) |
| Jun 2006 | - | $2.43M(-9.9%) |
| Mar 2006 | - | $2.69M(+16.9%) |
| Dec 2005 | $2.30M(+45.8%) | $2.30M(+27.2%) |
| Sep 2005 | - | $1.81M(+5.6%) |
| Jun 2005 | - | $1.72M(-11.0%) |
| Mar 2005 | - | $1.93M(+22.1%) |
| Dec 2004 | $1.58M(+477.7%) | $1.58M(-20.7%) |
| Sep 2004 | - | $1.99M(+53.9%) |
| Jun 2004 | - | $1.29M(+67.3%) |
| Mar 2004 | - | $773.20K(+182.8%) |
| Dec 2003 | $273.40K(-55.2%) | $273.40K(+5595.8%) |
| Sep 2003 | - | $4800.00(0.0%) |
| Jun 2003 | - | $4800.00(-66.7%) |
| Mar 2003 | - | $14.40K(-97.6%) |
| Dec 2002 | $610.10K(>+9900.0%) | $610.10K(>+9900.0%) |
| Sep 2002 | - | $4600.00(+39.4%) |
| Jun 2002 | - | $3300.00(-35.3%) |
| Mar 2002 | - | $5100.00 |
| Dec 2001 | $3300.00 | - |
FAQ
- What is Halozyme Therapeutics annual total liabilities?
- What is the all time high annual total liabilities for Halozyme Therapeutics?
- What is Halozyme Therapeutics annual total liabilities year-on-year change?
- What is Halozyme Therapeutics quarterly total liabilities?
- What is the all time high quarterly total liabilities for Halozyme Therapeutics?
- What is Halozyme Therapeutics quarterly total liabilities year-on-year change?
What is Halozyme Therapeutics annual total liabilities?
The current annual total liabilities of HALO is $1.70B
What is the all time high annual total liabilities for Halozyme Therapeutics?
Halozyme Therapeutics all-time high annual total liabilities is $1.70B
What is Halozyme Therapeutics annual total liabilities year-on-year change?
Over the past year, HALO annual total liabilities has changed by +$50.19M (+3.04%)
What is Halozyme Therapeutics quarterly total liabilities?
The current quarterly total liabilities of HALO is $1.71B
What is the all time high quarterly total liabilities for Halozyme Therapeutics?
Halozyme Therapeutics all-time high quarterly total liabilities is $1.77B
What is Halozyme Therapeutics quarterly total liabilities year-on-year change?
Over the past year, HALO quarterly total liabilities has changed by +$50.54M (+3.04%)